PASSCODE: Coordinating and Sharing PDAC stromal research data
Official title: PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education)
Funded at New York University School of Medicine · NIH-11413859 · Data updated 2026-11-12
A networked effort at NYU School of Medicine aims to study how the pancreatic cancer stroma shapes tumor growth and patient outcomes, by coordinating researchers, sharing data, and educating the field.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 16, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $993,577 |
| NIH project number | 5U24CA274274-05 |
| Project ID | NIH-11413859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic ductal adenocarcinoma or individuals contributing tissue or data for stromal research may be eligible through participating sites.
✕Less likely to help
The grant itself does not involve a new trial enrolling patients directly; benefits depend on subsequent therapies developed from stromal research.
What this research studies
This grant supports a center that coordinates six U01 sites studying the tumor microenvironment in pancreatic cancer, focusing on cancer-associated fibroblasts, the extracellular matrix, and other stromal components. It will manage data, standardize methods, and facilitate collaboration to accelerate discoveries that could influence future treatments. Researchers will combine basic science with translational aims to better understand how stroma affects disease progression and response to therapy. Patients may benefit in the long term as insights from this work inform novel approaches to targeting the tumor environment in pancreatic cancer.
Why it matters
Potential benefit: If successful, this effort could lead to new strategies that make pancreatic cancer more controllable by targeting the tumor stroma.
How similar studies have gone: Previous work indicates that the tumor stroma plays a critical role in PDAC biology and is a promising target for therapies; this program builds on that foundation with increased coordination and data sharing.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Maitra, Anirban — New York University School of Medicine
- Study coordinator: Maitra, Anirban
Related research
Other NIH-funded projects on the same topics.
-
Oncostatin M Receptor in Pancreatic Cancer
Aims to understand how a molecule called Oncostatin M and its receptor affect pancreatic cancer to find new ways to help patients.
-
Total Neoadjuvant Therapy for Borderline or Locally Advanced Pancreatic Cancer
A multi-part treatment approach tests giving all chemotherapy and targeted radiotherapy before surgery to help patients with tough-to-remove pancreatic cancer become eligible for curative surgery.
-
Low-dose, motion-aware MRI to study pancreatic cancer
A new MRI method using low-dose contrast and motion-resolved imaging is being explored to better characterize pancreatic cancer in patients.
-
SOAT1 as a target in pancreatic cancer
Researchers are studying a specific enzyme, SOAT1, to see if blocking it can slow down or stop pancreatic cancer progression in models that mimic human disease.
-
Turning inflammatory scar cells in the pancreas into helpers to improve treatment response
This project will try to change inflammatory, scar-forming cells around pancreatic tumors so treatments and the immune system can work better for people with pancreatic ductal adenocarcinoma.
-
Blocking cancer's iron supply to help pancreatic cancer drugs work better
This project tests whether stopping pancreatic cancer cells from using stored iron can help people with KRAS-mutant pancreatic ductal adenocarcinoma respond longer to new KRAS-targeting drugs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.